Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Life After CAR-T?
Life After CAR-T?
Is there life after CAR-T cell therapy? Almost everyone agrees that CAR-T cell therapy has a great deal of potential in the treatment of MM. Some even use the “C” word when talking about CAR-T cell therapy.
I think it makes sense to understand life after CAR-T therapy. Meaning, it’s in the MM patient’s best interest if they understand potential outcomes if they undergo CAR-T cell therapy.
The single most important sentence in the research linked below is ” the majority of patients relapse within 1 to 3 years following treatment.”
That fact tells me that MM patients about to undergo CAR-T cell therapy should work to improve their outcomes. MM patients should ask their oncologists how they can avoid being in the “majority of patients who relapse within 1 to 3 years following treatment”
Here’s a summary of what recent research has shown about precautions, optimizations, and supportive strategies that tend to enhance outcomes of CAR-T cell therapy in multiple myeloma (MM).
Key “Precautions” / Enhancers
These measures are not just “being careful” – many are proven (or promising) steps that improve efficacy, reduce complications, improve durability, or increase safety of CAR-T therapy in MM.
| Area | What’s known / Evidence | How it helps / Mechanism |
|---|---|---|
| Bridging Therapy / Tumor Burden Reduction | Many patients get bridging therapy while CAR-T cells are manufactured. Lower disease burden at CAR-T infusion correlates with better responses. | Reduces antigen load / tumor burden → may reduce “sink” effect; may allow CAR-T to function better, reduce risk of overwhelming CRS; possibly improves expansion/persistence. |
| Lymphodepletion Regimen (Preconditioning) | Choice and intensity of lymphodepleting chemo (usually fludarabine + cyclophosphamide) matter; optimal dosing schedules are under study. | Preconditioning helps by creating “space” (niches), reducing regulatory T/NK cells, lowering competition for cytokines, improving homeostatic proliferation and expansion of infused CAR-T. Too weak = poor expansion; too strong = toxicity. |
| Manufacturing / Vein-to-Vein Time | Delays during manufacturing (or low T-cell quality input) lead to worse outcomes. Efforts to optimize manufacturing, reduce failures, standardize processes improve results. | Faster turnaround means less progression during wait, fewer complications; better starting material means more robust CAR-T product (higher cellular quality, less exhaustion). |
| Infection Prophylaxis and Management | In MM patients with BCMA-targeted CAR-T, infections are common (both early and late). Prophylactic antibiotics/antivirals/antifungals are often recommended post-lymphodepletion and before infusion. | Helps prevent morbidity and mortality; infection can also impair CAR-T persistence, lead to treatment delays, or increase risk of severe CRS/neurotoxicity. |
| Management of Cytokine Release Syndrome (CRS) & Neurotoxicity | Early recognition, grading, and interventions (e.g. tocilizumab, corticosteroids) per established guidelines can reduce severity without compromising efficacy (if managed well). Supportive care critical. | Mitigates life-threatening complications; avoids interruptions or dose reductions; allows CAR-T therapy to be safer for more patients. |
| Patient Selection / Baseline Fitness | Patients with better performance status, less comorbidity, lower disease burden, and less heavy prior lines of therapy tend to do better. Also organ function, bone marrow reserve matter. | Less risk of complications; better ability to tolerate lymphodepletion; better immune repertoire for CAR-T expansion; less exhausted T cells. |
| Monitoring for Minimal Residual Disease (MRD) & Persistence | Durable MRD negativity correlates with longer progression-free survival (PFS) and overall survival (OS); persistence of CAR-T cells (or at least their functional impact) is linked with durability. | If you can maintain very low disease, relapse risk drops; persistence helps maintain control. |
| Supportive Care (nutrition, infection control, organ support) | Standard supportive care during CAR-T therapy (hydration, management of cytopenias, prophylaxis for tumor lysis, etc.) helps reduce non-CAR-T related mortality and morbidity. | Patients are vulnerable (due to prior therapy, lymphodepletion, immunosuppression); reducing “background” complications allows focus on the CAR-T effect. |
Please don’t be surprised if your oncologist, even if they are a MM specialist, does not know much about non-conventional “precautions or enhancers.” In my experience, conventional medicine knows little if anything about non-conventional therapies.
If you are considering CAR-T cell therapy it is in your interest to think outside the conventional thinking box.
I am a MM survivor and MM cancer coach. I have learned that conventional oncology, while central of managing MM, is only a piece of the MM picture. Email me at David.PeopleBeatingCancer@gmail.com to learn more about both conventional and non-conventional MM therapies.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Paramedullary disease (PMD) in multiple myeloma (MM)involves myeloma tumor masses growing from the bone marrow into adjacent tissues by disrupting the cortical bone. Unlike extramedullary disease (EMD), which grows independently of the bone, PMD is defined by its direct connection to a bone lesion
Post-Progression Outcomes Following BCMA-Directed CAR T-Cell Therapy in Myeloma: Impact of Extramedullary and Paramedullary Disease
BCMA-directed CAR T-cell therapies have improved outcomes in relapsed and refractory multiple myeloma (MM); however, the majority of patients relapse within 1 to 3 years following treatment.
Managing disease progression after CAR T-cell therapy remains a major challenge, particularly in aggressive subtypes including extramedullary disease (EMD) and paramedullary disease (PMD).
Real-world data on progression patterns post-CAR T cell therapy and the impact of EMD or PMD on outcomes of patients who relapsed post-CAR T-cell therapy remain scarce. In this single-center, retrospective study, we evaluated progression patterns and survival outcomes in 106 MM patients who progressed after commercial CAR T-cell therapy (ide-cel or cilta-cel) between May 2021 and December 2023.
Overall survival (OS) was defined from the time of post-CAR T-cell therapy progression to death or last follow-up, and progression-free survival (PFS) from post-CAR T-cell therapy progression to progression on the next line of therapy.
Biochemical relapse occurred in 82% of patients, with EMD or PMD present in 51% at progression. Baseline EMD at the time of CAR T-cell infusion was detected in 33% of patients and was associated with significantly inferior PFS (3.6 vs. 7.0 months, p=0.0076) and OS (4.8 vs. 21.0 months, p=0.00086) compared to those without EMD.
Similarly, the presence of EMD at progression was associated with shorter PFS (4.7 vs. 8.5 months, p=0.022) and OS (7.4 vs. 21.1 months, p=0.035). Patients who were EMD positive at both baseline and progression had the poorest outcomes. PMD at baseline or progression was not significantly associated with worse survival.
Our findings highlight that post-CAR T-cell progression in MM is heterogeneous and that EMD confers an adverse prognosis, emphasizing the critical need for imaging surveillance. Strategies such as bridging therapies aimed at reducing tumor burden prior to CAR T-cell infusion or maintenance therapies post-CAR T-cell therapy warrant further investigation to optimize responses and improve long-term survival in this high-risk population.
life after CAR-T life after CAR-T life after CAR-T